Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/9/2020
SIETES contiene 93095 citas

 1 a 20 de 346 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
DTB team. Are patient education materials for deprescribing fit for purpose?. Drug Ther Bull 2020;58:35. [Ref.ID 103637]
2.Tiene citas relacionadas Cita con resumen
Cave JA. Polypharmacy and deprescribing: just ask the patient. Drug Ther Bull 2020;58:2. [Ref.ID 103636]
3. Cita con resumen
Ostrow L, Jessell L, Hurd M, Darrow SM, Cohen D. Discontinuing psychiatric medications: a survey of long-term users . Psychiatric Services 2017;68:1232-8. [Ref.ID 101485]
4.Enlace a cita original
Barrenberg E, Garbe E. Use of over-the counter (OTC) drugs and perceptions of OTC drug safety among German adults. Eur J Clin Pharmacol 2015;71:1389-96. [Ref.ID 99626]
5.Enlace a cita original Cita con resumen
Feliz J. National study: teens report higher use of performance enhancing substances. Partnership for drug-free kids 2014:22 de julio. [Ref.ID 97750]
6. Cita con resumen
Spielmans GI, Kirsch I. Drug approval and drug effectiveness. Annual Review of Clinical Psychology 2014;214:741-66. [Ref.ID 97582]
Hull SC, Colloca L, Avins A, Gordon NP, Somkin CP, Kaptchuk TJ, Miller FG. Patients' attitudes about the use of placebo treatments: telephone survey. BMJ 2013;347:15. [Ref.ID 96122]
8.Enlace a cita original Cita con resumen
Hudson B, Zarifeh A, Young L, Wells JE. Patients' expectations of screening and preventive treatments. Ann Fam Med 2012;10:495-502. [Ref.ID 93236]
9. Cita con resumen
Fenton JJ, Jerant AF, Bertakis KD, Franks P. The cost of satisfaction. A national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med 2012;172:405-11. [Ref.ID 92513]
10.Enlace a cita original Cita con resumen
Anderson C, Krska J, Murphy E, Avery A, on behalf of the Yellow Card Study Collaboration. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective. Br J Clin Pharmacol 2011;72:806-22. [Ref.ID 91788]
11. Cita con resumen
Anónimo. Side effects have women stopping aromatase inhibitors early. DIA Daily 2011:12 de diciembre. [Ref.ID 91681]
12. Cita con resumen
Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment. A randomized trial. Ann Intern Med 2011;155:87-96. [Ref.ID 91391]
Moerman DE. Meaningful placebos - Controlling the uncontrollable. N Engl J Med 2011;365:171-2. [Ref.ID 90834]
15. Cita con resumen
Emery J, McKenzie A, Bulsara C, Holman D'Arcy. Next goal: consistency of packaging and labelling. BMJ 2010;341:64. [Ref.ID 88869]
16.Tiene citas relacionadas Cita con resumen
Licurse A, Barber E, Joffe S, Gross C. The impact of disclosing financial ties in research and clinical care. A systematic review. Arch Intern Med 2010;170:675-82. [Ref.ID 88423]
17.Tiene citas relacionadas Cita con resumen
Campbell EG. Public disclosure of conflicts of interest. Moving the policy debate forward. Arch Intern Med 2010;170:667. [Ref.ID 88421]
19. Cita con resumen
Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362:865-9. [Ref.ID 87995]
20. Cita con resumen
Godlee F, Chalmers I. Information about ongoing clinical trials for patients. BMJ 2010;340:456-7. [Ref.ID 87987]
Seleccionar todas
 1 a 20 de 346 siguiente >>